NEW YORK (GenomeWeb News) – GeneNews last night reported that its first-quarter revenues were flat year over year, while the firm cut its net loss 23 percent.

The Toronto-based genetic test maker brought in revenues of C$300,000 (US$255,000) for the three months ended March 31, the same amount it reported for the first quarter of 2008. GeneNews said that revenues for the quarter were derived from sales of its ColonSentry test for assessing an individual's risk for colorectal cancer, as well as a technology access fee it received from an unnamed company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.